Liraglutide Cost in Oregon 2026: Pricing, Insurance, and Savings Options

What Liraglutide Actually Costs in Oregon Right Now

The price you pay for liraglutide in Oregon depends almost entirely on how you source it. Three tiers exist. Brand-name Saxenda from Novo Nordisk carries a wholesale acquisition cost of $1,349 per month for the 3.0 mg weight-management dose [1]. Oregon retail pharmacies, after their own markups and distributor negotiations, charge a cash-pay average near $900 per month in 2026. And licensed 503A compounding pharmacies operating under Oregon Board of Pharmacy oversight can fill patient-specific liraglutide prescriptions for roughly $150 per month.

That six-fold price gap between brand and compounded product is not a quality gap in every case. Compounded liraglutide uses the same active pharmaceutical ingredient, but it is not FDA-approved as a finished product. The FDA permits 503A compounding when a licensed pharmacist prepares a medication pursuant to an individual prescription, a distinction that matters for both legality and insurance reimbursement [2]. Oregon patients choosing the compounded route save substantially but pay entirely out of pocket, since insurers do not reimburse compounded drugs.

For patients on a commercial insurance plan with liraglutide coverage, the effective monthly cost after co-pay card assistance can drop to $25 to $150 depending on formulary tier. Without insurance, the brand product remains one of the more expensive GLP-1 receptor agonists on the market, though it is less costly than semaglutide 2.4 mg (Wegovy), which lists above $1,300 per month and is frequently backordered [3].

The SCALE Obesity and Prediabetes trial (N=3,731) demonstrated that liraglutide 3.0 mg produced a mean weight loss of 8.0% at 56 weeks versus 2.6% with placebo [4]. That clinical efficacy profile is what Oregon providers weigh against the cost when choosing between GLP-1 options.

Oregon Medicaid Coverage for Liraglutide

Oregon Health Plan (Medicaid) covers liraglutide, but getting it requires prior authorization. The Oregon Health Authority's Practitioner-Managed Prescription Drug Plan includes GLP-1 receptor agonists on its preferred drug list for type 2 diabetes, while the weight-management indication (Saxenda) faces more restrictive criteria.

For type 2 diabetes, Oregon Medicaid typically requires documentation that metformin was tried first or is contraindicated. A prescriber must submit clinical notes showing the patient's HbA1c, current medications, and rationale for GLP-1 therapy [5]. Approval durations vary, but initial authorizations commonly run 6 to 12 months with renewal contingent on documented clinical response.

For chronic weight management, the PA criteria are tighter. Oregon Medicaid generally requires a BMI of 30 or greater (or 27 or greater with at least one weight-related comorbidity such as hypertension, dyslipidemia, or obstructive sleep apnea), failure of structured lifestyle intervention for at least 6 months, and prescribing by or in consultation with a provider experienced in obesity medicine. Denials can be appealed. The Oregon Health Authority publishes its PA criteria through the Drug Use Review / Pharmacy & Therapeutics Committee, and these documents are updated quarterly.

A 2024 Endocrine Society guideline update recommended GLP-1 receptor agonists as first-line pharmacotherapy for obesity in adults with BMI ≥30, stating that "the magnitude of weight reduction with GLP-1 receptor agonists supports their use as a primary pharmacologic intervention rather than a later-line option" [6]. Oregon Medicaid's step-therapy requirement for lifestyle intervention first does not fully align with that guideline, which may give providers ammunition for appeal letters.

Private Insurance Coverage Across Oregon

Commercial insurers in Oregon handle liraglutide coverage inconsistently. Plans from Moda Health, Providence Health Plan, PacificSource, and Regence BlueCross BlueShield each maintain their own formularies, and coverage for the weight-management indication (Saxenda) is less common than coverage for the diabetes indication (Victoza).

Most Oregon commercial plans cover Victoza (liraglutide 1.8 mg for type 2 diabetes) at Tier 3 or Tier 4 formulary status, with co-pays ranging from $50 to $200 per month after deductible. Saxenda coverage for weight management is more variable. Some large-group employer plans include anti-obesity medications as a benefit, while many individual-market and small-group plans exclude them entirely.

Dr. Caroline Apovian, a past president of The Obesity Society, has noted that "insurance coverage for FDA-approved anti-obesity medications remains the single largest barrier to treatment access in the United States" [7]. Oregon is no exception. Patients should call the number on the back of their insurance card and ask specifically whether "liraglutide for chronic weight management" is a covered benefit under their plan, because the diabetes and obesity indications often have different coverage determinations even though the molecule is identical.

The Novo Nordisk savings card program can reduce out-of-pocket costs for commercially insured patients to as low as $25 per month for up to 12 months, though eligibility excludes patients on government-funded insurance (Medicaid, Medicare, Tricare, VA). Patients must have commercial insurance that covers Saxenda to use the co-pay card. It does not function as a standalone discount.

Compounded Liraglutide in Oregon: Legality and Access

Compounded liraglutide is legal in Oregon when dispensed by a pharmacy operating under a valid 503A license from the Oregon Board of Pharmacy. Section 503A of the Federal Food, Drug, and Cosmetic Act permits pharmacies to compound medications for individual patients based on a valid prescription, provided the pharmacy does not compound in anticipation of receiving prescriptions (no batch manufacturing for general distribution) [2].

Oregon has several 503A-licensed pharmacies that compound liraglutide for subcutaneous injection. Pricing at these pharmacies typically falls between $125 and $200 per month, with $150 being a common price point in 2026. The compounded product is not bioequivalent-tested by the FDA, but reputable compounding pharmacies source their liraglutide API (active pharmaceutical ingredient) from FDA-registered facilities and perform potency and sterility testing on finished preparations.

Patients considering compounded liraglutide should verify three things. First, confirm the pharmacy holds a current Oregon Board of Pharmacy license. Second, ask whether the pharmacy performs third-party potency and sterility testing and can provide certificates of analysis. Third, confirm the pharmacy is compounding under 503A (patient-specific prescriptions) rather than 503B (outsourcing facility), since the regulatory requirements and oversight mechanisms differ [8].

The FDA has issued warning letters to compounding pharmacies nationally that marketed GLP-1 receptor agonists with misleading claims or without proper quality controls. Oregon patients should treat compounded liraglutide as a legitimate cost-saving option but exercise due diligence on pharmacy credentials.

How Oregon Telehealth Prescribing Works for Liraglutide

Oregon permits telehealth prescribing of liraglutide without requiring an in-person visit first. Under Oregon Revised Statutes (ORS 685.100 and related telehealth provisions), a provider licensed in Oregon can establish a patient-provider relationship via synchronous audio-video consultation and prescribe scheduled and non-scheduled medications, including injectable GLP-1 receptor agonists.

This means Oregon residents can obtain a liraglutide prescription from a telehealth platform without driving to a clinic. The prescription can then be filled at a retail pharmacy (for brand Saxenda), a mail-order pharmacy, or a licensed 503A compounding pharmacy. Several national telehealth platforms operate in Oregon and include liraglutide in their weight-management programs, with consultation fees typically running $99 to $199 for an initial visit and $49 to $99 for monthly follow-ups.

Telehealth providers must still perform appropriate clinical evaluation. That includes reviewing the patient's medical history, current medications, contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2), and BMI documentation [1]. A provider who prescribes liraglutide without this evaluation is cutting corners regardless of the visit modality.

One practical advantage of telehealth in Oregon: rural patients in areas like Eastern Oregon, where endocrinologists and obesity medicine specialists are scarce, can access prescribers who might otherwise require a multi-hour drive. The Oregon Office of Rural Health estimates that over 30 of Oregon's 36 counties qualify as rural or frontier, and telehealth has become the primary access pathway for specialty medication management in many of those areas.

Discount Programs and Cost-Reduction Strategies

Oregon patients have several pathways to reduce liraglutide costs beyond insurance coverage. Each has trade-offs worth understanding.

Novo Nordisk Savings Card. For commercially insured patients whose plan covers Saxenda, the manufacturer's co-pay card reduces out-of-pocket costs to as low as $25 per month. The card covers the gap between the patient's co-pay and the pharmacy's contracted rate. It does not apply to uninsured patients or those on government insurance. Enrollment is available through the Saxenda website or through a prescriber's office.

Pharmacy Discount Programs. GoodRx, RxSaver, and similar coupon aggregators show Oregon retail prices for Saxenda ranging from $780 to $1,050 per month depending on the pharmacy. These coupons do not stack with insurance but can help uninsured patients pay less than the full list price. Costco Pharmacy and some Fred Meyer locations in the Portland metro area tend to offer the lowest retail cash prices in the state.

503A Compounding. As noted above, compounded liraglutide at approximately $150 per month represents the lowest-cost option. This is a cash-pay pathway. Insurance will not reimburse compounded products, but the out-of-pocket cost is often less than a commercially insured patient's co-pay for brand Saxenda on a high-deductible plan.

Patient Assistance Programs. Novo Nordisk operates a Patient Assistance Program (PAP) for uninsured patients who meet income eligibility requirements (generally at or below 400% of the federal poverty level). Approved patients receive Saxenda at no cost. Processing takes 4 to 6 weeks, and approval is for 12 months with annual renewal [9].

Clinical Trials. ClinicalTrials.gov lists active GLP-1 studies recruiting in Oregon. Participants in qualifying trials may receive medication at no cost, though eligibility criteria are narrow and study protocols include additional monitoring requirements.

Liraglutide vs. Other GLP-1 Options Available in Oregon

Liraglutide is not the only GLP-1 receptor agonist prescribed in Oregon, and cost comparisons matter. Semaglutide 2.4 mg (Wegovy) lists at approximately $1,350 per month and produced 14.9% mean weight loss at 68 weeks in the STEP-1 trial (N=1,961) versus 2.4% with placebo [10]. Liraglutide 3.0 mg produced 8.0% mean weight loss at 56 weeks in SCALE [4]. The weight-loss difference is clinically meaningful, but so is the price difference when factoring in compounded liraglutide availability.

Tirzepatide (Zepbound) lists above $1,000 per month and showed 20.9% mean weight loss at 72 weeks in the SURMOUNT-1 trial (N=2,539) [11]. Tirzepatide is not yet available through 503A compounding in most Oregon pharmacies, which limits cost-reduction options.

For Oregon patients whose primary goal is cost-effective weight management and who are comfortable with the compounding pathway, liraglutide at $150 per month offers an accessible entry point to GLP-1 therapy. Patients who need or prefer FDA-approved brand product and have commercial insurance with coverage may find that Saxenda with a savings card is the most practical choice.

Safety Considerations Specific to Oregon Patients

Liraglutide carries a boxed warning for thyroid C-cell tumors based on rodent studies, and it is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2 [1]. The clinical relevance of the rodent findings to humans remains uncertain after more than a decade of post-marketing surveillance. A 2023 pharmacovigilance analysis of the FDA Adverse Event Reporting System found no statistically significant increase in medullary thyroid carcinoma reports among liraglutide users compared to background rates [12].

Common side effects include nausea (39% in SCALE), diarrhea (21%), constipation (19%), and injection-site reactions (13.9%) [4]. Nausea typically peaks during the dose-titration phase (weeks 1 through 5) and diminishes at steady state. Oregon prescribers generally follow the standard 5-week titration: 0.6 mg daily for week 1 to 1.2 mg for week 2 to 1.8 mg for week 3 to 2.4 mg for week 4, and 3.0 mg from week 5 onward.

Patients using compounded liraglutide should confirm that their pharmacy's product concentration matches the dosing instructions provided by their prescriber, since compounded preparations may differ in concentration from the brand Saxenda pen (6 mg/mL).